Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aquestive Therapeutics Inc AQST

Healthcare
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on... see more

Recent & Breaking News (NDAQ:AQST)

Aquestive Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration (FDA) for Tadalafil Oral Film

PR Newswire November 16, 2018

Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights

PR Newswire November 6, 2018

Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN™ (clobazam) Oral Film

PR Newswire November 2, 2018

Aquestive Therapeutics to Present at the Stifel 2018 Healthcare Conference

PR Newswire October 30, 2018

Aquestive Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Business Highlights on November 6, 2018

PR Newswire October 25, 2018

Aquestive Therapeutics Announces Completion of Diazepam Buccal Film Adult Epilepsy Monitoring Unit (EMU) Clinical Study with Positive Topline Results

PR Newswire October 25, 2018

Aquestive Therapeutics Names Lori J. Braender, Esq. as Senior Vice President, General Counsel

PR Newswire September 11, 2018

Aquestive Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights, Including Tentative Approval for Sympazan™

PR Newswire September 4, 2018

Aquestive Therapeutics Announces Tentative FDA Approval for Sympazan™ (clobazam) Oral Film

PR Newswire August 31, 2018

Aquestive Therapeutics Announces Closing of Exercise of Underwriters' Over-Allotment Option in Initial Public Offering

PR Newswire August 15, 2018

Aquestive Therapeutics Names Sandy Costa as Chairman of the Board of Directors

PR Newswire August 13, 2018

Aquestive Therapeutics to Present at the 2018 Wedbush Healthcare Conference

PR Newswire July 31, 2018

Aquestive Therapeutics Announces Closing of Initial Public Offering

PR Newswire July 27, 2018

Aquestive Therapeutics Announces Pricing of Initial Public Offering

PR Newswire July 24, 2018